Icaritin
- Generic Name
- Icaritin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20O6
- CAS Number
- 118525-40-9
- Unique Ingredient Identifier
- UFE666UELY
- Background
Icaritin has been used in trials studying the treatment of Solid Tumors, Metastatic Breast Cancer, and Hepatocellular Carcinoma (HCC).
- Associated Conditions
- -
- Associated Therapies
- -
Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06285149
Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Beijing Shenogen Biomedical Co., Ltd
- Target Recruit Count
- 261
- Registration Number
- NCT05594927
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
🇨🇳The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳Chifeng Municipal Hospital, Chifeng, Mongolia, China
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Beijing Shenogen Biomedical Co., Ltd
- Target Recruit Count
- 89
- Registration Number
- NCT03236649
- Locations
- 🇨🇳
First Affiliated Hospital Bengbu Medical College, Bengbu, Anhui, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing Hospital, Beijing, Beijing, China
The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Beijing Shenogen Biomedical Co., Ltd
- Target Recruit Count
- 312
- Registration Number
- NCT03236636
- Locations
- 🇨🇳
Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳The Sixth People's Hospital in Shenyang, Shenyang, Liaoning, China
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2015-07-14
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 28
- Registration Number
- NCT02496949
- Locations
- 🇨🇳
Cancer institute & hospital, chinese academy of medical sciences, Beijing, Beijing, China
The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2013-10-30
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Beijing Shenogen Biomedical Co., Ltd
- Target Recruit Count
- 70
- Registration Number
- NCT01972672
- Locations
- 🇨🇳
Beijing Shenogen Biomedical Co., Ltd, Beijing, Beijing, China
🇨🇳NanJing PLA 81 Hospital, Nanjing, Jiangsu, China
🇨🇳Cancer institute & hospital, chinese academy of medical sciences, Beijing, Beijing, China
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2011-01-28
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT01278810
- Locations
- 🇨🇳
Cancer institute & hospital, chinese academy of medical sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.